{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:39:19Z","timestamp":1793090359516,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["Article processing charges (Rapid Service"],"award-info":[{"award-number":["Article processing charges (Rapid Service"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["Open Access Fees) were funded by Novartis Pharma AG, Basel."],"award-info":[{"award-number":["Open Access Fees) were funded by Novartis Pharma AG, Basel."]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s12325-019-01134-x","type":"journal-article","created":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T16:02:53Z","timestamp":1573315373000},"page":"17-26","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Gathering Structured Patient Insight to Drive the PRO Strategy in COPD: Patient-Centric Drug Development from Theory to Practice"],"prefix":"10.1007","volume":"37","author":[{"given":"Francesco","family":"Patalano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian S.","family":"Gutzwiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavik","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitresh","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel S.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,9]]},"reference":[{"issue":"3","key":"1134_CR1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/2168479015622668","volume":"50","author":"G Borup","year":"2016","unstructured":"Borup G, Bach KF, Schmiegelow M, Wallach-Kildemoes H, Bjerrum OJ, Westergaard N. A paradigm shift towards patient involvement in medicines development and regulatory science: workshop proceedings and commentary. Ther Innov Regul Sci. 2016;50(3):304\u201311.","journal-title":"Ther Innov Regul Sci."},{"issue":"6","key":"1134_CR2","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jval.2016.04.009","volume":"19","author":"MM Lowe","year":"2016","unstructured":"Lowe MM, Blaser DA, Cone L, Arcona S, Ko J, Sasane R, et al. Increasing patient involvement in drug development. Value Health. 2016;19(6):869\u201378.","journal-title":"Value Health."},{"key":"1134_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00230","author":"D Haerry","year":"2018","unstructured":"Haerry D, Landgraf C, Warner K, Hunter A, Klingmann I, May M, et al. EUPATI and patients in medicines research and development: guidance for patient involvement in regulatory processes. Front Med. 2018. \nhttps:\/\/doi.org\/10.3389\/fmed.2018.00230\n\n.","journal-title":"Front Med."},{"issue":"Suppl 1","key":"1134_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/10810730.2011.589882","volume":"6","author":"BW Hesse","year":"2011","unstructured":"Hesse BW, O\u2019Connell M, Augustson EM, Chou W-YS, Shaikh AR, Rutten LJF. Realizing the promise of web 2 0: engaging community intelligence. J Health Commun. 2011;6(Suppl 1):10\u201331. \nhttps:\/\/doi.org\/10.1080\/10810730.2011.589882\n\n.","journal-title":"J Health Commun."},{"issue":"1","key":"1134_CR5","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s12913-016-1691-0","volume":"16","author":"E Smailhodzic","year":"2016","unstructured":"Smailhodzic E, Hooijsma W, Boonstra A, Langley DJ. Social media use in healthcare: a systematic review of effects on patients and on their relationship with healthcare professionals. BMC Health Serv Res. 2016;16(1):442. \nhttps:\/\/doi.org\/10.1186\/s12913-016-1691-0\n\n.","journal-title":"BMC Health Serv Res."},{"issue":"1","key":"1134_CR6","doi-asserted-by":"publisher","first-page":"00128","DOI":"10.1183\/23120541.00128-2018","volume":"5","author":"NS Cook","year":"2019","unstructured":"Cook NS, Kostikas K, Gruenberger JB, Shah B, Pathak P, Kaur VP, et al. Patients\u2019 perspectives on COPD: findings from a social media listening study. ERJ Open Res. 2019;5(1):00128\u20132018. \nhttps:\/\/doi.org\/10.1183\/23120541.00128-2018\n\n.","journal-title":"ERJ Open Res."},{"key":"1134_CR7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.2147\/COPD.S202580","volume":"14","author":"N Cook","year":"2019","unstructured":"Cook N, Gey J, Oezel B, Mackay AJ, Kumari C, Kaur VP, et al. Impact of cough and mucus on COPD patients: primary insights from an exploratory study with an online patient community. Int J Chronic Obstr Pulm Dis. 2019;14:1365.","journal-title":"Int J Chronic Obstr Pulm Dis."},{"key":"1134_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00082","author":"NS Cook","year":"2019","unstructured":"Cook NS, Cave J, Holtorf A-P. Patient preference studies during early drug development: aligning stakeholders to ensure development plans meet patient needs. Front Med. 2019. \nhttps:\/\/doi.org\/10.3389\/fmed.2019.00082\n\n.","journal-title":"Front Med."},{"key":"1134_CR9","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s12325-017-0557-0","volume":"34","author":"H Svedsater","year":"2017","unstructured":"Svedsater H, Roberts J, Patel C, Macey J, Hilton E, Bradshaw L. Life impact and treatment preferences of individuals with asthma and chronic obstructive pulmonary disease: results from qualitative interviews and focus groups. Adv Ther. 2017;34:1466\u201381.","journal-title":"Adv Ther."},{"issue":"2","key":"1134_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40271-013-0007-2","volume":"6","author":"G Pisa","year":"2013","unstructured":"Pisa G, Freytag S, Schandry R. Chronic obstructive pulmonary disease (COPD) patients\u2019 disease-related preferences. Patient. 2013;6(2):93\u2013101.","journal-title":"Patient."},{"key":"1134_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-981-10-4068-9_14","volume-title":"Patient involvement in health technology assessment","author":"J Street","year":"2017","unstructured":"Street J, Farrell L. Analysis of Social Media. In: Facey K, Hansen H, Single A, editors. Patient involvement in health technology assessment. Singapore: Springer Nature; 2017. p. 175\u201385."},{"key":"1134_CR12","doi-asserted-by":"publisher","unstructured":"Holtorf AP, Cook N. The role of patients in market access. In: Kockaya G, Wertheimer A, editors. Pharmaceutical market access in developed markets. SEED Open Books; 2018. pp. 267\u201388. \nhttps:\/\/doi.org\/10.7175\/747.ch18\n\n.","DOI":"10.7175\/747.ch18"},{"key":"1134_CR13","unstructured":"Mikolajczak C. Social media listening: uncovering patients\u2019 needs. 2017. \nhttps:\/\/pharmaphorum.com\/views-and-analysis\/social-media-listening-uncovering-patients-needs\/\n\n. Accessed 21 Aug 2019."},{"issue":"2","key":"1134_CR14","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.2196\/jmir.2912","volume":"16","author":"FJ Grajales III","year":"2014","unstructured":"Grajales III FJ , Sheps S, Ho K, Novak-Lauscher H, Eysenbach G. Social media: a review and tutorial of applications in medicine and health care. J Med Internet Res. 2014;16(2):e13.","journal-title":"J Med Internet Res."},{"issue":"4","key":"1134_CR15","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.2196\/jmir.1933","volume":"15","author":"SA Moorhead","year":"2013","unstructured":"Moorhead SA, Hazlett DE, Harrison L, Carroll JK, Irwin A, Hoving C. A new dimension of health care: systematic review of the uses, benefits, and limitations of social media for health communication. J Med Internet Res. 2013;15(4):e85. \nhttps:\/\/doi.org\/10.2196\/jmir.1933\n\n.","journal-title":"J Med Internet Res."},{"issue":"3","key":"1134_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2105\/ajph.2017.304249","volume":"108","author":"RF Hunter","year":"2018","unstructured":"Hunter RF, Gough A, O\u2019Kane N, McKeown G, Fitzpatrick A, Walker T, et al. Ethical issues in social media research for public health. Am J Public Health. 2018;108(3):343\u20138. \nhttps:\/\/doi.org\/10.2105\/ajph.2017.304249\n\n.","journal-title":"Am J Public Health"},{"key":"1134_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1139","author":"K El Emam","year":"2015","unstructured":"El Emam K, Rodgers S, Malin B. Anonymising and sharing individual patient data. Br Med J. 2015. \nhttps:\/\/doi.org\/10.1136\/bmj.h1139\n\n.","journal-title":"Br Med J."},{"issue":"6","key":"1134_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/13645579.2017.1281601","volume":"20","author":"G Guest","year":"2017","unstructured":"Guest G, Namey E, Taylor J, Eley N, McKenna K. Comparing focus groups and individual interviews: findings from a randomized study. Int J Soc Res Meth. 2017;20(6):693\u2013708.","journal-title":"Int J Soc Res Meth."},{"issue":"4","key":"1134_CR19","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s12325-019-00900-1","volume":"36","author":"NS Cook","year":"2019","unstructured":"Cook NS, Tripathi P, Weiss O, Walda S, George AT, Bushell A. Patient needs, perceptions, and attitudinal drivers associated with obesity: a qualitative online bulletin board study. Adv Ther. 2019;36(4):842\u201357. \nhttps:\/\/doi.org\/10.1007\/s12325-019-00900-1\n\n.","journal-title":"Adv Ther."},{"key":"1134_CR20","unstructured":"US Food and Drug Administration: Patient preference information\u2014voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling. 2016. \nhttps:\/\/www.fda.gov\/downloads\/medicaldevices\/deviceregulationandguidance\/guidancedocuments\/ucm446680.pdf\n\n. Accessed 28 Aug 2018."},{"issue":"6","key":"1134_CR21","first-page":"4","volume":"13","author":"J Bridges","year":"2007","unstructured":"Bridges J, Onukwugha E, Johnson F, Hauber A. Patient preference methods\u2014a patient centered evaluation paradigm. ISPOR Connect. 2007;13(6):4\u20137.","journal-title":"ISPOR Connect"},{"key":"1134_CR22","unstructured":"NICE. NICE provides first scientific advice on patient preference study design. \nhttps:\/\/www.nice.org.uk\/news\/article\/nice-provides-first-scientific-advice-on-patient-preference-study-design\n\n. Accessed 26 Aug 2019."},{"issue":"2","key":"1134_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1086\/259131","volume":"74","author":"KJ Lancaster","year":"1966","unstructured":"Lancaster KJ. A new approach to consumer theory. J Polit Econ. 1966;74(2):132\u201357.","journal-title":"J Polit Econ."},{"key":"1134_CR24","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/PPA.S140226","volume":"11","author":"FX Liu","year":"2017","unstructured":"Liu FX, Witt EA, Ebbinghaus S, DiBonaventura Beyer G, Shinde R, Basurto E, et al. Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment. Patient Prefer Adherence. 2017;11:1389\u201399. \nhttps:\/\/doi.org\/10.2147\/PPA.S140226\n\n.","journal-title":"Patient Prefer Adherence."},{"key":"1134_CR25","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2147\/COPD.S175706","volume":"14","author":"FM Franssen","year":"2019","unstructured":"Franssen FM, Alter P, Bar N, Benedikter BJ, Iurato S, Maier D, et al. Personalized medicine for patients with COPD: where are we? Int J Chron Obstr Pulmon Dis. 2019;14:1465.","journal-title":"Int J Chron Obstr Pulmon Dis."},{"issue":"149","key":"1134_CR26","doi-asserted-by":"publisher","first-page":"180022","DOI":"10.1183\/16000617.0022-2018","volume":"27","author":"VK Sidhaye","year":"2018","unstructured":"Sidhaye VK, Nishida K, Martinez FJ. Precision medicine in COPD: where are we and where do we need to go? Eur Respir Rev. 2018;27(149):180022.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"1134_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1465-9921-11-122","volume":"11","author":"A Agusti","year":"2010","unstructured":"Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11(1):122.","journal-title":"Respir Res"},{"issue":"11","key":"1134_CR28","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.rmed.2008.06.009","volume":"102","author":"B Crawford","year":"2008","unstructured":"Crawford B, Monz B, Hohlfeld J, Roche N, Rubin B, Magnussen H, et al. Development and validation of a cough and sputum assessment questionnaire. Respir Med. 2008;102(11):1545\u201355. \nhttps:\/\/doi.org\/10.1016\/j.rmed.2008.06.009\n\n.","journal-title":"Respir Med"},{"key":"1134_CR29","unstructured":"Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims US Food Drug Administration. 2009. \nhttps:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf\n\n. Accessed 28 Aug 2018."},{"issue":"Suppl 2","key":"1134_CR30","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1111\/j.1524-4733.2007.00271.x","volume":"10","author":"RR Turner","year":"2007","unstructured":"Turner RR, Quittner AL, Parasuraman BM, Kallich JD, Cleeland CS. Patient-reported outcomes: instrument development and selection issues. Value Health. 2007;10(Suppl 2):S86\u201393. \nhttps:\/\/doi.org\/10.1111\/j.1524-4733.2007.00271.x\n\n.","journal-title":"Value Health."},{"key":"1134_CR31","unstructured":"US Food and Drug Administration: Patient preference information\u2014voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling. Guidance for Industry, Food and Drug Administration Staff and Other Stakeholders In: CDRH, editor. Silver Spring: Office of Communication, outreach and Development; 2016."},{"issue":"3","key":"1134_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40271-017-0222-3","volume":"10","author":"EW de Bekker-Grob","year":"2017","unstructured":"de Bekker-Grob EW, Berlin C, Levitan B, Raza K, Christoforidi K, Cleemput I, et al. Giving patients\u2019 preferences a voice in medical treatment life cycle: the PREFER public\u2013private project. Patient. 2017;10(3):263\u20136. \nhttps:\/\/doi.org\/10.1007\/s40271-017-0222-3\n\n.","journal-title":"Patient."},{"key":"1134_CR33","unstructured":"US Food and Drug Administration: Patient-focused drug development: collecting comprehensive and representative input\u2014guidance for Industry, Food and Drug Administration staff, and other stakeholders [draft guidance]. \nhttps:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm610442.pdf\n\n. Accessed 26 Oct 2018."},{"key":"1134_CR34","unstructured":"US Food and Drug Administration: Patient-focused drug development public workshop on guidance 2: methods to identify what is important to patients. \nhttp:\/\/www.fda.gov\/downloads\/Drugs\/NewsEvents\/UCM620707.pdf\n\n. Accessed 26 Oct 2018."},{"key":"1134_CR35","unstructured":"US Food and Drug Administration: Patient-focused drug development public workshop on guidance 3: select, develop or modify fit-for-purpose clinical outcomes assessments. \nhttps:\/\/www.fda.gov\/downloads\/Drugs\/NewsEvents\/UCM620708.pdf\n\n. Accessed 26 Oct 2018."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01134-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01134-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01134-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T00:37:26Z","timestamp":1604795846000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01134-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,9]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1134"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01134-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,9]]},"assertion":[{"value":"3 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}